Skip to main content
Premium Trial:

Request an Annual Quote

Synthetic Genomics, ExxonMobil Ink New Agreement for Biofuel Development

NEW YORK (GenomeWeb News) – Synthetic Genomics today announced a new agreement with ExxonMobil to develop algae biofuels.

The new co-funded research agreement will focus on using synthetic genomic science and technology to develop algal strains "with significantly improved production characteristics," SGI said.

It and ExxonMobil originally reached a deal in 2009 to develop biofuel from photosynthetic algae that would be compatible with gasoline and diesel fuels. That collaboration hit a roadblock in 2011, however, when an algal strain failed to perform as desired, and ExxonMobil consequently scaled back the work from that contract, Bloomberg reported recently.

Today's agreement focuses on SGI core strengths in synthetic biology with an emphasis on basic scientific research "to develop strains which reproduce quickly, produce a high proportion of lipids and effectively withstand environment and operational conditions."

"The new agreement gives us an opportunity to really focus on improving algal strains using our core synthetic biology technologies to develop biofuels," SGI Founder and CEO J. Craig Venter said in a statement.

Financial and other terms were not disclosed.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.